• Indications
  • Open Access TIMES Journals
Login Register
Login Register
Indications
  • Oncology · Hematology
  • Spine Surgery
  • Cardiovascular
  • Diabetes + Endocrinology
  • Pneumology
  • Ophthalmology
  • Gynecology · Urology
  • Dermatology · Immunology · Rheumatology
  • Neurology · Psychiatry
  • Gastroenterology
  • Infectiology · Anesthesiology · Pain
  • Primary Care
Open Access TIMES Journals
  • Oncology · Hematology
  • Spine Surgery
  • Cardiovascular
  • Diabetes + Endocrinology
  • Pneumology
  • Ophthalmology
  • Gynecology · Urology
  • Dermatology · Immunology · Rheumatology
  • Neurology · Psychiatry
  • Gastroenterology
  • Infectiology · Anesthesiology · Pain
  • Primary Care
Oncology · Hematology

Oncology · Hematology

Case Reports
Expert Opinions
Congress News
E-Learning
Webinar
Faculty
healthbook TIMES
Homepage >
Oncology · Hematology >
Articles

Real-world evidence supports axi-cel in patients with R/R LBCL

Lymphoma
Share:
Do you want to read an article? Please log in or register.
Register for Free
Remember me
Forgot password? Click here
EHA 2026

Related content

CHICAGO 2026
Lymphoma
Real-world analysis demonstrates sustained responses with axi-cel in patients with R/R LBCL
ASH 2025
Lymphoma
Real-world comparison of commercial CAR T-cell therapies demonstrates comparable outcomes between axi-cel and liso-cel in R/R LBCL
EHA 2026
Lymphoma
Spanish multicenter real-world data show favorable outcomes with second-line axi-cel in R/R LBCL
ASH 2025
Lymphoma
Prognostic value of early MRD status in LBCL patients treated with axi-cel or liso-cel
EHA 2026
Leukemia
Real-world analysis demonstrates high remission rates and a manageable safety profile of brexu-cel in patients with B-ALL
EHA 2026
Lymphoma
First real-world CIBMTR data show high response rates and early durable benefit with liso-cel in R/R MCL
ASH 2025
Lymphoma
French Register data confirm robust efficacy of axi-cel and liso-cel in early-relapsing LBCL
CHICAGO 2026
Lung, Respiratory and Thoracic Cancer
Jazz EMERGE 402: Final primary analysis supports real-world effectiveness of lurbinectedin in patients with previously treated ES-SCLC
Lung, Respiratory and Thoracic Cancer
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort
J Thorac Oncol
Illini O, Hund AC, Kopp HG, Moskovitz M, Mountzios G, Brueckl WM, Früh M, Leßmann ME, Christopoulos P, Stenzinger A, Thomas M, Gillis R, Peled N, Acker F, Addeo A, Charpidou A, Grohé C, Mauti L, Rothschild SI, Schmid S, Schumann C, Urban D, Wurm R, Ekman S, Skribek M, Glanemann F, Wiesweg M, Ackermann CJ, Agelaki S, Hoffknecht P, Jakopović M, Kern J, König D, Kostenzer K, Kropf-Sanchen C, Laack E, Lang D, Nagl L, Pall G, Reck M, Kian W, Allemann AT, Alt J, Araújo D, Bokas A, Hannah F, Julie KJ, Weinlinger C, de Langen AJ, Fergadis EG, Fountzilas E, Froesch P, Frost N, Griesinger F, Jordan F, Karanikiotis C, Kiesewetter B, Korantzis I, Machado AL, Economopoulou P, Pilz A, Reimann P, Rittmeyer A, Saad A, Samitas K, Schulmann K, Shah R, Stratmann JA, Taghizadeh H, Tammoscheit K, Tufman A, Weber JP, Wöll E, Valipour A, Overbeck TR, Hochmair MJ
doi: 10.1016/j.jtho.2026.103651
  • Contact us
  • About us
  • Privacy Policy & Disclaimer
  • Online Media 2026 Data
  • Imprint
healthbook is a registered trademark. Copyright © 2026 healthbook